Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
104 results about "Lung metastasis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
What is a Lung Metastasis A lung metastasis is a cancerous growth in the lung that got its start from cancer cells originating somewhere else in the body. Cancer cells that spread to and take root in the lungs are said to have “metastasized” the lung.
Aerosol Drug Inhibition of Lung Cancer
The present invention provides a method of inhibiting growth of lung metastases in an individual comprising the steps of administering a dose of a lipid-drug enhancer liposomal complex and, in sequence, administering a dose of a lipid-anticancer drug liposomal complex. Furthermore, the lipid-drug enhancer liposomal complex may be administered in a continuing dose with the lipid-anticancer drug liposomal complex whereby both liposomal complexes are mixed in the nebulizer. Methods of inhibiting growth of lung metastases in an individual by the sequential administration via aerosolization of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex and a dilauroylphosphatidylcholine-paclitaxel liposomal complex are also provided.
Owner:KNIGHT J VERNON +2
Aerosol drug inhibition of lung metastases
The present invention provides a method of inhibiting growth of lung metastases in an individual comprising the steps of administering a dose of a lipid-drug enhancer liposomal complex and, in sequence, administering a dose of a lipid-anticancer drug liposomal complex. Furthermore, the lipid-drug enhancer liposomal complex may be administered in a continuing dose with the lipid-anticancer drug liposomal complex whereby both liposomal complexes are mixed in the nebulizer. Methods of inhibiting growth of lung metastases in an individual by the sequential administration via aerosolization of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex and a dilauroylphosphatidylcholine-paclitaxel liposomal complex are also provided.
Owner:RES DEVMENT FOUND
Pharmaceutical composition having function cancer of the lungs against
InactiveCN101152408AHigh activityGrowth inhibitionAntineoplastic agentsPlant ingredientsSide effectElutriation
A medicine combination has the function of resisting lung cancer. The combination is mixed with rhizoma paridis saponin and milk vetch root amylose according to the weight ratio of 3 to 1. The rhizoma paridis is extracted by alcohol and then the rhizoma paridis extract is obtained through gradient elutriation of macroporous absorption resin alcohol; the milk vetch root is extracted by water and then the protein is settled and removed to get the milk vetch root amylose; the two extracts are mixed and the medicine is made. The MTT activities experiment in vitro with the MTT method has proven that the medicine combination can obviously control the growth of various lung cancer cells such as LA795 lung adenocarcinoma cell and the IC50 can reach 26.73 ug / ml; the experiment of mouse with the lung cancer tumor has represented that the tumor constraint rate can reach 55.63 percent; in this way, lung transfer of hypodermic transplanted tumor of the mouse with the lung cancer tumor can be obviously controlled and the tumor cells can be brought to death; moreover, spleen index and thymus index can be promoted and the medicine is innocuous and has no side effect. In addition, compared with the raw materials, the medicine combination has high activity and clear function; moreover, the medicine can be made into different types.
Owner:TIANJIN UNIV
Carcinoma Homing Peptide (CHP), Its Analogs, and Methods of Using
ActiveUS20120208770A1Inhibit tumor growthImprove survivalOrganic active ingredientsPeptide/protein ingredientsSquamous CarcinomasWild type
A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE
Albumin-loaded manganese dioxide and perflubron nanoparticles as well as preparation method and application thereof
PendingCN111821279AFacilitate ablationGrowth inhibitionMaterial nanotechnologyNanomagnetismBovine serum albuminHigh-intensity focused ultrasound
The invention discloses albumin-loaded manganese dioxide and perflubron nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biology, and the albumin-loaded manganese dioxide and perflubron nanoparticles are prepared from bovine serum albumin-loaded manganese dioxide and perflubron. The invention further provides a preparation method of the albumin-loaded manganese dioxide and perflubron nanoparticle and application of the albumin-loaded manganese dioxide and perflubron nanoparticle in tumor bimodal imaging and enhancement of high-intensity focused ultrasound tumor immunogenic death. The invention has the advantages that the albumin-loaded manganese dioxide and perflubron nanoparticles obtained by the preparation method have the characteristics of enhancing high-intensity focused ultrasound immune death and biocompatibility and being high in active targeting enrichment amount in tumors, and tumor diagnosis and real-time monitoringcan be realized through CT and MRI bimodal imaging; by enhancing high-intensity focused ultrasound tumor immunogenic death, tumor growth and lung metastasis can be inhibited in vivo, and the survivalrate of animals can be increased.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling blood coagulation factor VIII level to play anti-tumor role and application thereof
ActiveCN110028546APrevent proliferationInhibition of adhesionSteroidsAntineoplastic agentsBlood coagulation factor VIIIFactor ii
The invention provides a cyclopentanopolyhydrophenanthrene skeleton compound capable of regulating and controlling the blood coagulation factor VIII level to play an anti-tumor role, and application of the cyclopentanopolyhydrophenanthrene skeleton compound to preparation of drugs for treating blood coagulation factor VIII-mediated tumors, in particular to drugs for treating a blood coagulation factor VIII-mediated tumor which is blood coagulation factor VIII-mediated liver cancer. Experiments prove that the cyclopentanopolyhydrophenanthrene skeleton compound can inhibit expression and secretion of HUVEC endothelial cells FVIII, inhibit HUVEC endothelial cell FVIII mediated hepatoma carcinoma cell proliferation, and inhibit adhesion of tumor cells and platelets mediated by FVIII secreted by HUVEC cells, and in-vivo experiments prove that the cyclopentanopolyhydrophenanthrene skeleton compound can inhibit lung metastasis of liver cancer by inhibiting the level of FVIII.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
RAB22A-NoeFs fusion gene system for diagnosing and/or treating osteosarcoma, and application thereof
ActiveCN108949768APromote migrationPromote invasionOrganic active ingredientsMicrobiological testing/measurementExonNucleotide sequencing
The invention discloses a fusion gene line RAB22A-NoeFs for diagnosing and / or treating osteosarcoma. The first and second exons of the RAB22A gene are fused with the 54408036th to 54476718th positionof chromosome 20 after being inversed, the fusion gene line includes the following six fusion genes: RAB22A-NoeF1, RAB22A-NoeF2, RAB22A-NoeF3, RAB22A-NoeF4, RAB22A-NoeF5 and RAB22A-NoeF6, and the nucleotide sequences of the fusion genes are sequentially represented by SEQ ID NO:1-6. The six fusion genes of the fusion gene line RAB22A-NoeFs can promote the migration and invasion of osteosarcoma cells, wherein the RAB22A-NoeF1 has above functions, and also can promote the lung metastasis of the osteosarcoma cells. The fusion gene line RAB22A-NoeFs can be used as a specific therapeutic target forosteosarcoma, and has a great application prospect.
Owner:SUN YAT SEN UNIV CANCER CENT
Lung-targeting metastatic human hepatoma cell strain and establishing method thereof
InactiveCN101831405AHigh strengthDelayed quenching timeMicroorganism based processesTumor/cancer cellsEpitheliumFluorescence
The invention provides a lung-targeting metastatic human hepatoma cell strain and an establishing method thereof. The lung-targeting metastatic human hepatoma cell strain is characterized in that the mother cell is a red fluorescent protein expression hepatoma cell HCCLM3-R; the cell is named as a lung-targeting metastatic human hepatoma cell strain HCCLM3-R-LM1 by classifying, has the preservation number of 3644, and has the following biological characteristics that the cell is in polygonal epithelium shape, grows clinging to the wall, loses contact growth inhibition, has a hypo-triploid caryogram with the chromosome number of 50-58, secretes AFP protein, and has lung-targeting metastatic clonal selection advantage. The establishing method comprises the following steps of: sieving by adopting nude mouse subcutis and liver orthotopic implantation tumour model autogenetic lung metastasis, and then carrying out in-vitro cloning, purifying and propagating on the lung-targeting metastatic human hepatoma cell. The invention has wide application potential and potential societal and economic benefits in basic research of hepatoma and clinic previous research of medicines.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Use of Liriope muscari Bailey C in pharmacy
ActiveCN101352448AGrowth inhibitionInhibit migrationOrganic active ingredientsAntineoplastic agentsMelanomaLymphatic Spread
The invention belongs to the field of pharmacy, and discloses the application of rusogenin fucopyranoside C in the pharmacy. The invention also provides the application of the rusogenin fucopyranoside C in the preparation of the medicine for resisting tumor metastasis, and more particularly relates to the application in the preparation of the medicine for generating tumour new blood vessels and inhibition of relative tumor metastasis. Being proved by the study of the invention, the rusogenin fucopyranoside C can effectively inhibit the growth, migration and adhesive ability, can inhibit lung metastasis of melanoma B16, and provides new selection in the application of preparing the medicine for resisting tumor metastasis.
Owner:TIANJIN TASLY PHARMA CO LTD
Chemotherapy-immunotherapy combined drug and preparation method and application thereof
PendingCN113350283AStrong activationGrowth inhibitionOrganic active ingredientsPharmaceutical non-active ingredientsNucleotideCD8
The invention discloses a chemotherapy-immunotherapy combined drug and a preparation method and application thereof. A PTX micelle based on PEG-P (CL-DTC) is designed, and the technical effect of combination of the PTX micelle and vesicles (CPs-CDN) with asymmetric membrane structures of interferon-gene-carrying stimulating protein (STING) pathway agonist Cyclic Dinucleotide (CDN) in treatment of breast cancer (TNBC) is studied. The PTX micelle is simple in preparation method, small in particle size and high in drug loading capacity and has good stability and reduction responsiveness. Experiments show that after the PTX micelle is combined with the CPs-CDN, more BMDC maturation can be promoted, CD4<+> T and CD8<+> T cells in tumors and spleens are significantly increased, inhibitory Treg is reduced, tumor growth and lung metastasis are obviously inhibited, the lifetime of mice is prolonged, and the advantages of chemotherapy-immunotherapy are embodied.
Owner:SUZHOU UNIV
Animal model constructing method for studying epithelial and stromal hyalinosis of hepatocellular carcinoma
InactiveCN102178568AEasy to manufactureIncrease success ratePreparing sample for investigationBiological testingCancer cellLymphatic Spread
The invention provides an animal model constructing method for studying epithelial and stromal hyalinosis of hepatocellular carcinoma. The method is characterized by the following steps: inoculating cancer cells to liver of an experimental animal in situ under guidance of ultrasonic equipment; and dynamically observing related index changes and lung metastasis conditions of epithelial and stromal hyalinosis. The method has the advantages that: the manufacturing process is simple and easy, has high success rate, and can be widely popularized and applied; and the manufactured animal mode can truly simulate the pathological process of clinical metastasis of hepatic carcinoma, and can dynamically reflect the developing process of the epithelial and stromal hyalinosis of the hepatic carcinoma.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
siRNA capable of inhibiting MAT2A genetic expression and application of siRNA
ActiveCN105039342ASuppress generationPrevent invasionOrganic active ingredientsFermentationDiseaseNucleotide
The invention discloses siRNA capable of inhibiting MAT2A genetic expression and application of the siRNA. The positive-sense strand of siRNA MAT2A-1 capable of inhibiting the MAT2A genetic expression is shown as SEQ ID NO:2, and the antisense strand of the siRNA MAT2A-1 is shown as SEQ ID NO:3. The positive-sense strand of siRNA MAT2A-2 capable of inhibiting the MAT2A genetic expression is shown as SEQ ID NO:4, and the antisense strand of the siRNA MAT2A-2 is shown as SEQ ID NO:5. Lentivirus vector transfection liver cancer cells of lentivirus expression vector combination overexpression MAT1A genes built according to the siRNA inhibiting the MAT2A genetic expression successfully inhibit hepatocellular carcinoma angiogenesis, migration, invasion and lung metastasis, the nucleotide sequence of the MAT1A genes is shown as the 256th-144th bases of SEQ ID NO.1. The siRNA can be further applied to preparing medicine treating liver cancer diseases and has high theoretical and application value.
Owner:李家平 +3
A medicinal preparation for treating breast cancer and preparation method thereof
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Naphthalimide derivative and preparing method and application thereof
ActiveCN105622507APrevent acetylationOrganic active ingredientsOrganic chemistryHepg2 cellsK562 cells
The invention relates to a naphthalimide derivative and an application thereof.The naphthalimide derivative is of the structure in the formula I or the formula II.The aphthalimide derivative shows obvious inhibitory activity for proliferation of multiple tumor cells such as HCT-116 cells, HepG2 cells, K562 cells and SMMC-7721 cells, and lung metastasis of tumors can be effectively inhibited in the body.
Owner:HENAN UNIVERSITY
Mouse model with lung metastasis of gastric cancer and establishment method thereof
InactiveCN107006429AImprove transfer efficiencyAssessing the science of transfer methodsMammal material medical ingredientsMaterial analysisAbnormal tissue growthLymphatic Spread
The invention relates to a mouse model with lung metastasis of gastric cancer and an establishment method thereof, and belongs to the technical field of experimental animals. According to the mouse model and the establishment method thereof, BGC-823 and MKN-45 gastric cancer cells are cultured in vitro, and resuspended to a proper concentration with sterile PBS when the cell viability is strong. After the cells are cultured inside the body of immunodeficient NUDE and SCID mice inoculated in immunodeficience through the caudal vein, the mouse model with lung metastasis of gastric cancer is successfully obtained by the identifications including the statistics of surface lung nodules, HE staining and IHC staining. According to the mouse model establishment, needed experimental conditions and operation are simple and convenient, lung metastasis lesions after the experiment are obvious, metastasis efficiency is high, and mice with metastatic lesions have moderate survival cycles. In the evaluation and statistics of the metastasis results, the macroscopic counting of the lung nodules is improved into the microscopic counting of the IHC staining positive cells, thereby obtaining more objective and accurate results. The animal model of tumor metastasis may be widely used in scientific research and teaching.
Owner:JIANGSU UNIV
Hexamethoxyflavanone-rhamnosyl-rhamnoside and application thereof
ActiveCN105061533AObvious migrationApparent aggressivenessSugar derivativesSugar derivatives preparationOncologyColon cancer cell
The invention belongs to the technical field of medicine, and relates to a hexamethoxyflavanone-rhamnosyl-rhamnoside and application thereof. The hexamethoxyflavanone-rhamnosyl-rhamnoside is prepared by the following steps: carrying out solvent extraction and extraction separation on murraya jasminorage, carrying out silica gel column separation, carrying out further separation by semipreparative chromatography, concentrating, and carrying out freeze-drying to obtain the finished hexamethoxyflavanone-rhamnosyl-rhamnoside product. The antitumor activity evaluation detects that the hexamethoxyflavanone-rhamnosyl-rhamnoside has low cytotoxicity; the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on the adhesion of colon cancer cells HT-29 and Fn (fibronectin) and the adhesion of HUVECs (human umbilical vein endothelial cells); the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on migration capacity (scratch heating experiment) and invasion capacity of HT-29; and the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on mouse in-vivo B16-F10 lung transfer. Therefore, the hexamethoxyflavanone-rhamnosyl-rhamnoside has tumor transfer inhibition activity, can be used for preparing anticancer drugs, and has favorable development and application prospects.
Owner:FUZHOU UNIV
Application of polypeptide Kp-10 in preparation of medicine for treating and preventing osteosarcoma
PendingCN111467478APrevent proliferationAbility to inhibit migrationPeptide/protein ingredientsSkeletal disorderClinical prognosisReceptor
The invention discloses an application of a polypeptide Kp-10 in preparation of a medicine for treating and preventing osteosarcoma. The amino acid sequence of the polypeptide Kp-10 is DSSDSSDSSDSSDSSDSSYNWNSFGLRF. Researches find that expression of GPR54 / KiSS-1 in osteosarcoma tissues is obviously lower than that in normal tissues beside the tumor tissues, and is highly related to clinical prognosis, and the polypeptide Kp-10 and a receptor GPR54 of the polypeptide Kp-10 can inhibit proliferation and migration capacity and lung metastasis capacity of osteosarcoma cells, so that the polypeptide Kp-10 can be used for preparing medicines for treating and preventing osteosarcoma, and a new thought is provided for exploration of osteosarcoma targeted medicine.
Owner:SHANGHAI CHANGZHENG HOSPITAL
4-aminopyrrolopyrimidine derivative and preparation method and application thereof
ActiveCN111100130ANovel structureInhibition of activityOrganic active ingredientsOrganic chemistryDiseaseStage melanoma
The invention relates to a 4-aminopyrrolopyrimidine derivative and a preparation method and application thereof, and belongs to the field of medicines. The invention provides a compound shown as a formula I or pharmaceutically acceptable salt thereof. The compound can significantly inhibit the activity of RIPK1 kinase, has high selectivity and good safety, and is a potential therapeutic drug for RIPK1 kinase related diseases. TNF alpha induced SIRS model and mouse melanoma lung metastasis model experiments prove that the compound disclosed by the invention can play a role in inhibiting RIPK1 kinase in vivo and has remarkable anti-inflammatory and anti-tumor metastasis activity. The invention provides a new strategy and means for comprehensively treating tumor metastasis.
Owner:SICHUAN UNIV
Angiopoietin-like 4 and its use in modulating cell leakiness
Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin [alpha]5[beta]1, VEcadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin [alpha]5[beta]1-mediated Rac1 / PAK signaling to weaken cell-cell contacts. Subsequently, cANGPTL4 is associated with and declusters VE-cadherin and claudin-5, leading to endothelial disruption. Interfering with the formation of these cANGPTL4 complexes delayed vascular disruption. In vivo vascular permeability and metastatic assays performed using ANGPTL4-knockout and wild-type mice injected with either control or ANGPTL4-knockdown tumors confirmed that cANGPTL4 induced vascular leakiness and facilitated lung metastasis in mice. Therefore, our findings elucidate how cANGPTL4 induces endothelial disruption. Our findings have direct implications for targeting cANGPTL4 to treat cancer and other vascular pathologies.
Owner:NANYANG TECH UNIV
Carcinoma homing peptide (CHP), its analogs, and methods of using
ActiveUS9657077B2Promote accumulationAccelerate the accumulation processImpression capsPeptide/protein ingredientsSquamous CarcinomasWild type
A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE
Application to promotion of cervical squamous cell carcinoma metastasis based on DDX19A
ActiveCN112813162AEasy transferPromote migrationMicrobiological testing/measurementAntineoplastic agentsCell invasionSquamous Carcinomas
The invention belongs to the technical field of medical products, and discloses an application to promotion of squamous cell carcinoma metastasis based on DDX19A. In function, DDX19A is found to promote in-vitro migration and invasion of cervical squamous cell carcinoma cells and in-vivo lung metastasis. In terms of mechanism, overexpression of the DDX19A increases NOX1 expression, increases production of reactive oxygen species (ROS), and induces migration and invasion of the cervical squamous cell carcinoma cells. Rescue experiments show that overexpression of NOX1 can retrieve and knock down cervical cancer squamous cell carcinoma cell invasion and migration and ROS generation caused by DDX19A, and the inventor further discovers that an ROS inhibitor N-acetylcysteine can inhibit DDX19A-induced cervical squamous cell carcinoma cell invasion and migration. Therefore, the DDX19A is proved to promote metastasis of the cervical squamous cell carcinoma by inducing NOX1 to mediate ROS production. Blocking of a DDX19A / NOX1 / ROS axis can be a potential therapeutic target for patients with cervical squamous cell carcinoma.
Owner:THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
Preparation method and application of liver-restoring tablet
ActiveCN103599493ARich in active ingredientsReduce dosageDigestive systemPill deliveryActive ingredientLungs metastasis
The invention provides a preparation method for a liver-restoring tablet. The liver-restoring tablet is prepared from the bulk drugs consisting of 800 g of isatis root, 166 g of oriental wormwood, 266 g of curcuma tuber, 266 g of Chinese magnoliavine, 266 g of licorice, 133 g of Chinese angelica, 400 g of milk vetch and 200 g of acanthopanax root through supercritical extraction. With the preparation method, the content of the bulk drugs in the liver-restoring tablet is greatly increased, and the dose of the tablet is reduced. The invention further provides application of the liver-restoring tablet in preparation of drugs used for inhibiting cell proliferation of the mouse melanoma lung metastasis strain B16-F10.
Owner:海宁市钱塘新农村开发有限公司
Lung metastasis prediction method for patients with limb soft tissue sarcoma
ActiveCN110084800AGood predictive abilityImprove predictive abilityImage enhancementImage analysisClinical informationFeature extraction
The invention discloses a lung metastasis prediction method for patients with limb soft tissue sarcoma, and the method comprises the steps: S1, carrying out the feature extraction of all to-be-testedobjects through employing a standard shooting value of a PET image, wherein the features comprises an SUV feature and a texture feature; s2, carrying out feature extraction on all tested clinical information by using a one-hot encoding method; and S3, performing feature contribution degree sorting on all the features by using a random forest algorithm, fusing the high contribution degree features,and constructing a lung metastasis prediction model of the patient with the limb soft tissue sarcoma by using a BP neural network. The lung metastasis prediction method can predict the lung metastasis condition of patients with limb soft tissue sarcoma more accurately by using fewer patient characteristics.
Owner:SHANGHAI MARITIME UNIVERSITY
Rotundic acid derivant having effect of preventing and treating tumour metastasis
ActiveCN107200769AImprove solubilityGood physical and chemical propertiesOrganic active ingredientsSteroidsAbnormal tissue growthLymphatic Spread
The invention provides application of a rotundic acid derivant in preparation of a medicine for preventing and treating tumour metastasis. An in vitro experiment proves that the rotundic acid derivant disclosed by the invention has significant inhibition effects on proliferation, adhesion, migration and the like of tumor cells, and is safe and low-toxicity to normal cells of a human body. An in vivo animal experiment proves that experimental lung metastasis of B16-F10 melanoma of mice can be effectively reduced, and a preferable tumour metastasis prevention effect is prompted. The rotundic acid derivant disclosed by the invention can be applied to a medicine for preventing the tumour metastasis, so that new application of the rotundic acid derivant to prevention and treatment of tumors is developed, and a new choice is provided for developing a new drug for treating the tumour metastasis and preventing postoperative re-metastasis of malignant tumour; moreover, the rotundic acid derivant has more obvious pharmacological activity.
Owner:JILIN ACAD OF TRADITIONAL CHINESE MEDICINE
Cell line of renal sarcomatoid carcinoma in persons of Han nationality and preparation method thereof
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Anti-human YKL-40 neutralizing monoclonal antibody as well as preparation and application thereof
ActiveCN112375147AInhibit lung metastasisAntibody ingredientsTissue cultureAntiendomysial antibodiesAmino acid
The invention relates to the technical field of medical bioengineering, in particular to an anti-human YKL-40 neutralizing monoclonal antibody. The amino acid sequence of a heavy chain variable regionof the monoclonal antibody is shown as SEQ ID NO:1, and the amino acid sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO:2. According to the invention, uniquesequence information of the monoclonal antibody is provided, and a hybridoma cell strain secreting the monoclonal antibody and application of the monoclonal antibody and the hybridoma cell strain inpreparation of drugs for inhibiting lung metastasis of liver cancer are also provided.
Owner:中国人民解放军海军军医大学第三附属医院
Calcium phosphate-lipid nano-drug co-delivery system consisting of low molecular weight heparin and prodrug of natural drug
ActiveCN110960507AInhibit EMT processInhibition formationHydroxy compound active ingredientsInorganic non-active ingredientsPhosphorylationNeo angiogenesis
The invention relates to the field of pharmaceutical preparations, and relates to a calcium phosphate-lipid nano-drug co-delivery system consisting of low molecular weight heparin and a prodrug of a natural drug and a preparation method for the nano-drug co-delivery system. According to the nano-drug co-delivery system, nanoparticles prepared from a biodegradable lipid material are taken as carriers, and the phosphorylated prodrug PIC-POOH of the natural drug piceatannol (PIC) is physically entrapped, and the low molecular weight heparin (LMWH) adsorbs on the outer layers of the carriers by static electricity; and a nano preparation concentrates at a tumor site by utilizing the long circulating performance of the nano preparation and the enhanced permeability and retention (EPR) effect ofa solid tumor tissue, a related pathway for tumor cell metastasis is then regulated, angiogenesis is inhibited, and the anti-tumor metastasis action is exerted. Proved by assays, the nano-drug co-delivery system can inhibit the epithelial-mesenchymal transition (EMT) progress of tumor cells; proved by a tube formation assay, the nano-drug co-delivery system can significantly inhibit tumor angiogenesis; proved by in vivo administration evaluation, the nano-drug co-delivery system can reduce formation of lung metastasis on a mice model, and prolongs the survival time of tumor-bearing mice; and the nano-drug co-delivery system has an obvious anti-tumor metastasis effect, especially reduces triple negative breast cancer metastasis, and has high safety.
Owner:FUDAN UNIV
Tumor models employing green fluorescent protein
InactiveUS7749486B2Better quantitative tumor burden assessmentGood curative effectUltrasonic/sonic/infrasonic diagnosticsSurgeryGreen fluorescent proteinCancer therapy
The present invention relates to a LOX-GFP marker and methods of analyzing tumor burden in ascites or in lung. The invention also relates to a new LOX-GFP-LM cell line which demonstrates increased lung metastasis. The methods of the invention result in better quantitative tumor burden assessment and improved efficacy evaluation. These improved models provide a feasible alternative for ascites or experimental metastasis evaluation of novel cancer therapeutics.
Owner:F HOFFMANN LA ROCHE & CO AG
Methods and compositions for treating melanoma
PendingUS20220220565A1Short survival timeKeep for a long timeOrganic active ingredientsMicrobiological testing/measurementMetastatic melanomaInvasive Melanoma
The present invention relates to a method and composition for treating melanoma, aggressive / invasive melanoma, metastatic melanoma or melanoma resistant. More particularly, inventors have shown that high expression of PTX3 correlates with melanoma invasiveness and with a poorer survival rate in metastatic melanoma patients. PTX3 knockdown inhibited melanoma cell migration, invasion, lung metastasis, and NFκB signaling pathway. An addition of melanoma-derived or recombinant PTX3, or overexpression of PTX3 enhanced motility of low migratory cells. Finally, they found that TLR4 and MYD88 knockdown or targeting inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4 / NFκB-dependent pathway. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma, aggressive / invasive melanoma, metastatic melanoma or melanoma resistant by quantifying the expression level of PTX3 in a biological sample and to a method of treating melanoma, aggressive / invasive melanoma, metastatic melanoma or melanoma resistant by using the inhibitors of PTX3.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
Pentamethine-cyanine-dye photosensitive dye with long lifetime of excited state, and preparation method and application thereof
ActiveCN113384695AExcited state lifetime is longIncreased singlet oxygen quantum yieldOrganic chemistryPhotodynamic therapyQuantum yieldCancer cell
The invention provides a pentamethine-cyanine-dye photosensitive dye with a long lifetime of excited state and a preparation method and application thereof. The photosensitive dye has a structure shown in a general formula I. The pentamethine-cyanine-dye photosensitive dye with long lifetime of excited state can have relatively high singlet oxygen quantum yield and relatively long lifetime of excited state. Under the excitation of near-infrared light, the photodynamic killing can be carried out on normoxic and hypoxic cancer cells. Meanwhile, the pentamethine-cyanine-dye photosensitive dye with a long lifetime of excited state possesses a good application prospect in the aspects of treating solid tumors in vivo and inhibiting lung metastasis of cancer cells.
Owner:DALIAN UNIV OF TECH
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com